Skip to Content

'
Judith K. Wolf, MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology, Blanton Davis Ovarian Cancer Research Program, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Associate Director, Department of Gynecologic Oncology, Developmental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Graduate Faculty, Biomedical Sciences, Graduate School of Biomedical Sciences, The University of Texas Houston Health Science Center, Houston, TX

Bio Statement

Judith K. Wolf, MD, is a Professor in the Department of Gynecologic Oncology at the University of Texas M. D. Anderson Cancer Center.

After receiving a bachelor’s degree from the University of Akron, Dr. Wolf earned her medical degree from Northeastern Ohio Universities College of Medicine. She completed a residency in obstetrics and gynecology at the University of Texas Health Science Center at San Antonio and a fellowship in gynecologic surgery at the University of Minnesota. Additionally, she completed clinical and research fellowships in gynecologic oncology at the University of Texas M. D. Anderson Cancer Center and earned a master’s degree in biomedical sciences from the University of Texas Health Science Center at Houston. In 1995, Dr. Wolf joined the faculty of M. D. Anderson Cancer Center.

Dr. Wolf’s research on gynecologic cancers has been published in journals including Gynecologic Oncology, Obstetrics and Gynecology, International Journal of Oncology, and Clinical Cancer Research. She continues to conduct research, particularly in the area of gene therapy for ovarian cancer.

Currently she is involved in laboratory research trying to improve the current gene therapy delivery systems and targeting that are available and clinically involved in several clinical trials evaluating chemotherapy agents, as well as, anti-angiogenic agents in the treatment of gynecologic malignancies. 

Dr. Wolf is also active in local and national societies regarding gynecologic malignancies including Society of Gynecologic Oncology, The American Society of Clinical Oncology, The American Association of Cancer Research, The Houston Gynecologic and Obstetrics Society, of which she is President in 2003, and she is the head of the Board-of-Directors of the National Ovarian Cancer Coalition. The National Ovarian Cancer Coalition’s main goal is education of women and primary care physicians about the signs and symptoms of ovarian cancer. Dr. Wolf is also the Chair person and founder of the 5K fun run Sprint for Life which has thus to date raised over two million dollars for ovarian cancer research and is held each May here at M. D. Anderson Cancer Center. 

Office Address

The University of Texas M. D. Anderson Cancer Center
1155 Hermann Pressler
Unit 1362
Unit Number: Unit 1362
Houston, TX 77030
Room Number: CPB6.3255
Phone: 713-792-7310
Fax: 713-745-8276
Email: jwolf@mdanderson.org

Education & Training

Postgraduate Training

1993-1995 Junior Faculty Associate, Gynecologic Oncology, UT M.D. Anderson Cancer Center, Houston, TX, Dr. J. Taylor Wharton
1991-1993 Fellow, Gynecologic Oncology, Department of Biology, UT M.D. Anderson Cancer Center, Houston, TX, Dr. J Taylor Wharton
1990-1991 Fellowship, Gynecologic Surgery, University of Minnesota, Duluth, MN, Dr. Leo Twiggs
1986-1990 Residency, Obstetrics and Gynecology, U.T. Health Science Center at San Antonio, San Antonio, TX, Dr. Carl J. Pauerstein

Board Certifications

2000 American Board of Obstetrics and Gynecology: Special Qualification in Gynecologic Oncology
1997 American Board of Obstetrics and Gynecology
1996 American Board of Obstetrics and Gynecology: Special Qualification in Gynecologic Oncology
1990 American Board of Obstetrics and Gynecology

Experience/Service

Academic Appointments

Co-Division Director, Department of Gynecologic Oncology, Division of Surgery, Baylor College of Medicine, Houston, TX, 4/2006-4/2007
Associate Professor, Department of Gynecologic Oncology, Blanton Davis Ovarian Cancer Research Program, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2006-8/2008
Associate Professor, Department of Gynecologic Oncology, Division of Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2002-8/2008
Assistant Professor, Department of Gynecologic Oncology, Division of Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1999-2002
Assistant Professor, Department of Gynecologic Oncology, Division of Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 1995-1999

Administrative Appointments/Responsibilities

Medical Director, Community Relations, Department of Gynecologic Oncology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 4/2008-present
Assistant Program Director (Research), Fellowship in Gynecologic Oncology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1999-2004

Other Appointments/Responsibilities

Member, Governing Board, National Ovarian Cancer Coalition, Boca Raton, FL, 2007-present
Chairman, Medical Advisory Board, National Ovarian Cancer Coalition, Boca Raton, FL, 2003-present
President, Houston Gynecologic & Obstetrics Society, Houston, TX, 2003-2004
Member, Gynecologic Oncology Group, Philadelphia, PA, 2001-present
Vice President, Houston Gynecologic & Obstetrics Society, Houston, TX, 2001
Chairman, Felix Rutledge Society, Houston, TX, 1999
Member, National Ovarian Cancer Coalition, Boca Raton, FL, 1998-present
Member, Medical Advisory Board, National Ovarian Cancer Coalition, Boca Raton, FL, 1998-present
Chairman, Sprint for Life 5K Fun Run, M. D. Anderson Cancer Center, Houston, TX, 1998-present
Treasurer, Houston Gynecologic & Obstetrics Society, Houston, TX, 1998-2000
Member, Breakthrough Series; Improving Care at the End of Life, Houston, TX, 1997-present
Member, Society of Gynecologic Oncologists, Chicago, IL, 1996-present

Institutional Committee Activities

Member, Women Faculty Programs, 8/2009-present
Member, Clinical Research Committee, 7/2009-present
Member, Clinical Research Counsel, 6/2008-present
Award Nomination Selection Committee, Womens faculty Programs, 5/2008-present
Head, Gynecologic Oncology Committee for New Institute of Personalized Cancer Therapy, 4/2008-present
Member, Executive Committee of Faculty Senate, Women's Advisory Committee, 2007-2009
Member, Faculty Senate, Committee, 2006-present
Member, Faculty Leadership Committee, 2006-present
Chairman, Ovarian Working Group, Department of Gynecologic Oncology, 2005-present
Member, Search Committee, Department of Nephrology Chair, 2005
Member, Gynecologic Oncology T32 - Program Steering Committee, 2005
Co-Principal Investigator, The University of Texas M. D. Anderson Cancer Center, Gynecologic Oncology Group (GOG), 2005
Chairman, Faculty Celebration Gala, 2005
Member, Gynecologic Oncology Surgical Research Program (GO-SRP) Committee, 2004-present
Member, Fellowship Planning Committee, 2004-present
Member, Blanton-Davis Ovarian Cancer Research Program Executive Committee, 2004-present
Member, Faculty Celebration Steering Committee, 2004
Member, Gynecologic Oncology Center for Surgical Research (GOCSR), 2004
Member, Uterine SPORE Executive Committee, 2003-present
Member, Faculty Promotion and Tenure Committee, Division of Surgery, 2003-present
Member, Clinical Research Committee, 2001-2004
Member, Search Committee, Internal Medicine, 2001
Reviewer, Cancer Therapeutics Discovery Program Grants, 2000-2004
Member, Ovarian SPORE Executive Committee, 1999-present
Member, Search Committee, Anesthesia, 1999-2000
Faculty Reviewer, Student and Trainee Resources-Clinical Fellow's Research Award, 1999
Member, Cancer Committee, Hermann Hospital, 1998-2001
Member, Women's Faculty Administrative Organization Steering Committee, 1998-1999
Member, Clinical Research Committee, 1997-2000
Member, Medical Records Committee, 1995-present

Professional Memberships

American Association of Cancer Research
Member, 1996-present
American Board of Obstetrics & Gynecology, Dallas, TX
Oral Board Examiner, 12/2008
American College of Obstetrics and Gynecology
Fellow, 1999-present
American Gynecological & Obstetrical Society
Fellowship, 11/2007-present
American Society of Clinical Oncology
Member, 1997-present
Felix Rutledge Society
President Elect, 2008-2009
Felix Rutledge Society
Member, 1996-present
Government Relations Committee, Society of Gynecologic Oncologist
Co-Chair, 2005-present
Government Relations Committee, Society of Gynecologic Oncologist
Member, 2002-present
Gynecologic Oncology Group, Developmental Therapeutics Committee
Member, 2001-present
Gynecologic Oncology Group, Phase I Subcommittee
Member, 2004-present
Houstion Gynecology & Obstetrics Society
Member, 2004-present
Houston Gynecology & Obstetrics Society
President, 2003-2004
Houston Gynecology & Obstetrics Society
President-Elect, 2002-2003
Houston Gynecology & Obstetrics Society
Vice President, 2001
Houston Gynecology & Obstetrics Society
Treasurer, 1998-2000
Houston Gynecology & Obstetrics Society, Houston, TX
Member, 1996
Ob-Gyn Alumni Association, The University of Texas Health Science Center at San Antonio, San Antonio, TX
Member, 1999
Program Committee, Felix Rutledge Society
Chariman, 1999
Program Committee, Felix Rutledge Socity
Co-Chairman, 2007
Program Committee, Society of Gynecologic Oncologist
Member, 1999
Society of Gynecologic Oncology
Member, 1996-present
Southern Regional Professional Development Conference for Women in Medicine and Research, Take charge of Your Life: Speak Up, Stand Out, and Stay Calm
Planning Committee, 3/2007

Selected Publications

Peer-Reviewed Original Research Articles
1. Chmura K, Shishodia S, Ramondetta LM, Wolf JK, Aggarwal BB, Chan ED. Curcumin inhibits the proliferation of SPEC-2 cells, a uterine papillary serous carcinoma cell line. Clin Cancer Research. In Press.
2. Tung CS, Mok S, Deavers M, Liu J, Malpica A, Lu KH, Tsang-Lee YT, Zu Z, Wolf JK, Gershenson DM, Song H. Pax2 expression in low-grade ovarian serous carcinomas. Modern Pathology. In Press.
3. Tanyi JL, MD, Smith JA, Ramos LM, Parker C, Munsell M, Wolf JK. Predisposing Risk Factors for Palmar-Plantar Erythrodysesthesia When Using Liposomal Doxorubicin to Treat Recurrent Ovarian Cancer. Gynecologic Oncology. In Press.
4. Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, Spannuth WA, Tanaka T, Shahzad MMK, Lin YG, Nick AM, Danes CG, Lee JW, Jennings NB, Vivas-Mejia PE, Wolf JK, Coleman RL, Siddik ZH, Lopez-Berestein G, Lutsenko S, Sood AK. Therapeutic targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res 15(11):3770-80, 6/1/2009. e-Pub 5/26/2009. PMID: 19470734.
5. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, Iyer RB, Wolf JK, Levenback CL, Gershenson DM, Freedman RS. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 113(2). e-Pub 3/4/2009. PMID: 19264351.
6. Gaikwad A, Wolf JK, Brown J, Ramondetta LM, Smith JA. In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines. J Oncol Pharm Pract 15(1):35-44, 3/2009. e-Pub 8/27/2008. PMID: 18753181.
7. Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA. Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA). Cancer Treat Rev 35(1). e-Pub 2/2009. PMID: 18922643.
8. Ramirez PT, Schmeler KM, Wolf JK, Brown J, Soliman PT. Robotic radical parametrectomy and pelvic lymphadenectomy in patients with invasive cervical cancer. Gynecol Oncol 111(1):18-21, 10/2008. e-Pub 7/18/2008. PMID: 18639329.
9. Smith JA, Gaikwad A, Yu J, Wolf JK, Brown J, Ramondetta L, Stewart C. In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines. Cancer Chemother Pharmacol 62(1):51-58, 2008. e-Pub 9/12/2007. PMID: 17849119.
10. Tung CS, Soliman PT, Wallace MJ, Wolf JK, Bodurka DC. Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens. Gynecol Oncol 107(1):140-2, 10/2007. e-Pub 8/1/2007. PMID: 17669477.
11. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 105(2):399-403, 2007.
12. Saucier JM, Yu J, Wolf JK, Coleman R, Smith JA. Determination of the optimal combination chemotherapy regimen for the treatment of platinum-resistant ovarian cancer in a nude mouse model. J Oncol Pharm Prac 13(1):39-46, 2007.
13. Soper JT, Spillman M, Sampson JH, Kirkpatrick JP, Wolf JK, Clarke-Pearson DL. High-risk gestational trophoblastic neoplasia with brain metastases: individualized multidisciplinary therapy in the management of four patients. Gynecol Oncol 104(3):691-4, 2007.
14. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2):404-8, 2007.
15. Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105(2)(2):404-8, 2007. e-Pub 2/9/2007. PMID: 17292461.
16. Tung CS, Soliman PT, Wallace MJ, Wolf JK, Bodurka DC. Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens. Gynecol Oncol 107(1):140-142, 2007.
17. Smith JA, Gaikwad A, Ramondetta LM, Wolf JK, Brown J. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecol Oncol 103(2):518-22, 11/2006. PMID: 16690105.
18. Wolf JK, Bodurka DC, Verschraegen C, Sun CC, Branham D, Jenkins AD, Atkinson N, Gershenson DM. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Gynecol Oncol 102(3)(3):468-74, 9/2006. e-Pub 3/3/2006. PMID: 16516276.
19. Coleman RL, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Levenback CF, Gershenson DM. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol 101(1)(1):126-31, 4/2006. e-Pub 11/3/2005. PMID: 16271384.
20. Frumovitz M, Coleman RL, Gayed IW, Ramirez PT, Wolf JK, Gershenson DM, Levenback CF. Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Am J Obstet Gynecol 194(4)(4):1186-93; discussion 1193-5, 4/2006. PMID: 16580331.
21. Smith JA Gaikwad A, Ramondetta LM, Wolf JK, Brown J. Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines. Gynecol Oncol 103(2):518-22, 2006.
22. Maluf FC, Leiser AL, Aghajanian C, Sabbatini P, Pezzulli S, Chi DS, Wolf JK, Levenback C, Loh E, Spriggs DR. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 16(3):1165-71, 2006.
23. Smith JA, Ngo H, Martin MC, Wolf JK. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines. Gynecol Oncol 98(1):141-5, 7/2005. PMID: 15963813.
24. Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol 97(3)(3):916-23, 6/2005. PMID: 15907981.
25. Jenkins AD, Ramondetta LM, Sun C, Johnston T, Wolf JK, Bodurka DC, Brown J, Atkinson EN, Levenback C. Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. Gynecol Oncol 97(3)(3):840-4, 6/2005. PMID: 15882895.
26. Sood AK, Coleman RL, Wolf JK, Gershenson DM. Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004. Expert Opin Pharmacother 6(7):1269-75, 6/2005. PMID: 15957979.
27. Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4)(4):219-27, 4/2005. e-Pub 11/9/2004. PMID: 15538640.
28. Slomovitz, Wolf J, Ramondetta LM, Burke TW, Lu KH. Advances in the management of advanced and recurrent uterine papillary serous carcinoma. Int J Gynecol Cancer (accepted in press), 2005.
29. Wolf Slomovitz BM. Novel biologic therapies for the treatment of endometrial cancer. Int J Gynecol Cancer (accepted in press), 2005.
30. Ramirez PT, Frumovitz M, Wolf JK, Levenback C. Laparoscopic port-site metastases in patients with gynecological malignancies. Int J Gynecol Cancer 14(6)(6):1070-7, Nov-Dec, 11/2004. PMID: 15571612.
31. Wolf JK, Bodurka DC, Gano JB, Deavers M, Ramondetta L, Ramirez PT, Levenback C, Gershenson DM. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 94(2)(2):442-8, 8/2004. PMID: 15297186.
32. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 33(12):1219-24, 6/2004. PMID: 15122311.
33. Smith JA, Brown J, Martin MC, Ramondetta LM, Wolf JK. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 92(1):314-9, 2004. PMID: 14751176.
34. Christen, Muller P, Wathen K, Wolf J. Bayesian randomized clinical trials: A decision-theoretic sequential design. Can J Stat 32(4):387-402, 2004.
35. Frumovitz, Ramirez PT, Greer M, Gregurich MA, Wolf J, Bodurka DC, Levenback C. Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training. Gynecol Oncol 94:746-753, 2004.
36. Ramirez PT, Wolf JK, Levenback C. Laparoscopic port-site metastases: etiology and prevention. Gynecol Oncol 91(1)(1):179-89, 10/2003. PMID: 14529679.
37. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, Levenback CF, Broaddus R. A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets. Gynecol Oncol 90(3)(3):529-36, 9/2003. PMID: 13678720.
38. Gordinier ME, Malpica A, Burke TW, Bodurka DC, Wolf JK, Jhingran A, Ramirez PT, Levenback C. Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy. Gynecol Oncol 90(3):625-8, 9/2003. PMID: 13678736.
39. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 9(10 pt 1)(10 Pt 1):3534-45, 9/2003. PMID: 14506139.
40. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Jr, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90(1):44-50, 7/2003. PMID: 12821340.
41. Huh JJ, Wolf JK, Fightmaster DL, Lotan R, Follen M. Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells. Gynecol Oncol 89(2):243-50, 5/2003. PMID: 12713987.
42. Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 63(5)(5):1073-82, 3/2003. PMID: 12615725.
43. Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM. Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol 21(2)(2):291-7, 1/2003. PMID: 12525521.
44. Trimble, Bell M, Wolf J, Alvarez R. Grantsmanship and career development for gynecologic cancer investigators. Cancer S 98(9):2075-2082, 2003.
45. Ramondetta LM, Bodurka DC, Tortolero-Luna G, Gordinier M, Wolf JK, Gershenson DM, Sciscione AC. Mentorship and productivity among gynecologic oncology fellows. J Cancer Educ 18(1)(1):15-9, 2003. PMID: 12825629.
46. Fracasso, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. Gynecol Onc 90:177-80, 2003.
47. Modesitt SC, Tortolero-Luna G, Robinson JB, Gershenson DM, Wolf JK. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 100(4)(4):788-95, 10/2002. PMID: 12383550.
48. Ramirez PT, Wolf JK, Malpica A, Deavers MT, Liu J, Broaddus R. Wolffian duct tumors: case reports and review of the literature. Gynecol Oncol 86(2):225-30, 8/2002. PMID: 12144833.
49. Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res 8(7):2413-22, 7/2002. PMID: 12114447.
50. Ramirez PT, Modesitt SC, Morris M, Edwards CL, Bevers MW, Wharton JT, Wolf JK. Functional outcomes and complications of continent urinary diversions in patients with gynecologic malignancies. Gynecol Oncol 85(2)(2):285-91, 5/2002. PMID: 11972389.
51. Dalrymple JL, Levenback C, Wolf JK, Bodurka DC, Garcia M, Gershenson DM. Trends among gynecologic oncology inpatient deaths: is end-of-life care improving? Gynecol Oncol 85(2):356-61, 5/2002. PMID: 11972400.
52. Tanyi, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, Gu J, Fang B, Mills GB, Wolf JK. Identification of tissue and cancer selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 85(3):451-458, 2002.
53. Ramirez PT, Gershenson DM, Tortolero-Luna G, Ramondetta LM, Fightmaster D, Wharton JT, Wolf JK. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53. Gynecol Oncol 83(3)(3):543-8, 12/2001. PMID: 11733969.
54. Levenback C, Coleman RL, Burke TW, Bodurka-Bevers D, Wolf JK, Gershenson DM. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol 83(2)(2):276-81, 11/2001. PMID: 11606084.
55. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol 82(3)(3):420-6, 9/2001. PMID: 11520135.
56. Robinson JB, Singh D, Bodurka-Bevers DC, Wharton JT, Gershenson DM, Wolf JK. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 82(3):550-8, 9/2001. PMID: 11520154.
57. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G, Hung MC. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19(14)(14):3422-33, 7/2001. PMID: 11454891.
58. Ramirez PT, Levenback C, Burke TW, Eifel P, Wolf JK, Gershenson DM. Sigmoid perforation following radiation therapy in patients with cervical cancer. Gynecol Oncol 82(1):150-5, 7/2001. PMID: 11426977.
59. Modesitt SC, Ramirez P, Zu Z, Bodurka-Bevers D, Gershenson D, Wolf JK. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 7(6):1765-72, 6/2001. PMID: 11410518.
60. Munkarah A, Levenback C, Wolf JK, Bodurka-Bevers D, Tortolero-Luna G, Morris RT, Gershenson DM. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 81(2):237-41, 5/2001. PMID: 11330956.
61. Parker LP, Ramirez PT, Broaddus R, Sightler S, Wolf JK. Low-grade ovarian cancer in an adolescent patient. Gynecol Oncol 80(1)(1):104-6, 2001. PMID: 11136580.
62. Gordinier ME, Ramondetta LM, Parker LP, Wolf JK, Follen M, Gershenson DM, Bodurka-Bevers D. Survey of female gynecologic oncologists and fellows: balancing professional and personal life. Gynecol Oncol 79(2)(2):309-14, 11/2000. PMID: 11063663.
63. Parker LP, Wolf JK, Price JE. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines. Ann Clin Lab Sci 30(4)(4):395-405, 10/2000. PMID: 11045764.
64. Bodurka-Bevers D, Basen-Engquist K, Carmack CL, Fitzgerald MA, Wolf JK, de Moor C, Gershenson DM. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 78(3)(3 Pt 1):302-8, 9/2000. PMID: 10985884.
65. Ramondetta L, Mills GB, Burke TW, Wolf JK. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res 6(1)(1):278-84, 2000. PMID: 10656459.
66. Donato, Gershenson D, Ippoliti C, Wharton JT, Bast Jr RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant 25(11):1137-1140, 2000.
67. Verschraegen, Levenback C, Vincent M, Wolf J, Bevers M, Loyer E, Kudelka AP, Kavanagh JJ. Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan. Annals NY Acad Sci 922:349-51, 2000.
68. Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma. Cancer 86(11):2291-300, 12/1999. PMID: 10590370.
69. Wolf JK, Mills GB, Bazzet L, Bast RC, Roth JA, Gershenson DM. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol 75(2)(2):261-6, 11/1999. PMID: 10525383.
70. Wolf JK, Kim TE, Fightmaster D, Bodurka D, Gershenson DM, Mills G, Wharton JT. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol Oncol 73(1)(1):27-34, 4/1999. PMID: 10094876.
71. Wolf JK, Mullen J, Eifel PJ, Burke TW, Levenback C, Gershenson DM. Radiation treatment of advanced or recurrent granulosa cell tumor of the ovary. Gynecol Oncol 73(1):35-41, 4/1999. PMID: 10094877.
72. Bodurka-Bevers, Basen-Engquist KM, Fitzgerald MA, Bevers MW, Wolf JK, Levenback C, Gershenson DM. Depression may worsen quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 72:449, 1999.
73. Brader KR, Wolf JK, Chakrabarty S, Price JE. Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol Rep 5(5)(5):1269-74, Sep-Oct, 9/1998. PMID: 9683849.
74. Gershenson DM, Silva EG, Levy L, Burke TW, Wolf JK, Tornos C. Ovarian serous borderline tumors with invasive peritoneal implants. Cancer 82(6)(6):1096-103, 3/1998. PMID: 9506355.
75. Price JE, Wolf JK, Pathak S. Distinctive karyotypes and growth patterns in nude mice reveal cross-contamination in an established human cancer cell line. Oncol Rep 5(1)(1):261-6, Jan-Feb, 1998. PMID: 9458333.
76. Brader KR, Wolf JK, Hung MC, Yu D, Crispens MA, van Golen KL, Price JE. Adenovirus E1A expression enhances the sensitivity of an ovarian cancer cell line to multiple cytotoxic agents through an apoptotic mechanism. Clin Cancer Res 3(11):2017-24, 11/1997. PMID: 9815592.
77. Wolf JK, Levenback C, Malpica A, Morris M, Burke T, Mitchell MF. Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. Obstet Gynecol 88(1)(1):82-6, 7/1996. PMID: 8684768.
78. Levenback C, Morris M, Burke TW, Gershenson DM, Wolf JK, Wharton JT. Groin dissection practices among gynecologic oncologists treating early vulvar cancer. Gynecol Oncol 62(1)(1):73-7, 7/1996. PMID: 8690296.
79. Gershenson DM, Morris M, Burke TW, Levenback C, Wolf JK, Warner D, Matthews CM, Wharton JT. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin(BEP). Obstet Gynecol 87(4):527-31, 4/1996. PMID: 8602303.
80. Hamada K, Zhang WW, Alemany R, Wolf J, Roth JA, Mitchell MF. Growth inhibition of human cervical cancer cells with recombinant adenovirus p53 in vitro. Gynecol Oncol 60(3):373-379, 1996.
81. Mitchell MF, Hamada K, Jagannadha S, Satterfield WC, Buchholz S, Wolf JK, Zhang WU, Alemany R, Tortolero-Luna G, Keeling ME, Wharton JT, Roth JR. Transgene expression in the rhesus cervix mediated by an adenovirus expressing b-galactosidase. Am J Obstet Gynecol 174:1094-1101, 1996.
82. Hamada K, Zhang WW, Alemany R, Roth JA, Wolf JK, Mitchell MF. Gene therapy of cervical cancer by adenovirus-mediated p53 gene transfer. J Cell Biochem Suppl 21A:421, 1995.
83. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53(4):891-8, 2/1993. PMID: 8094034.

Invited Articles
1. Wolf JK. Prevention and treatment of vaginal stenosis resulting form pelvic radiation therapy. Community Oncol 3(10):665-71, 2006.
2. Wolf J, Slomovitz BM. Novel biologic therapies for the treatment of endometrial cancer. Int J Gynecol Cancer 15(2):411, 2005.
3. Markman, Gershenson DM, Wolf J. Controversies in Ovarian Cancer. ACOG Update 30:1-9, 2004.
4. Soliman PT, Slomovitz BM, Wolf JK. Mechanisms of cervical cancer. Drug Discov Today: Dis Mech 1(2):253-258, 2004.
5. Slomovitz B, Soliman P, Wolf J. New standards for treating recurrent ovarian cancer. NOCC 19(Summer):5, 2004.
6. Wolf JK, Franco EL, Arbeit JM, Shroyer KR, Wu TC, Runowicz CD, Tortolero-Luna G, Herrero R, Crum CP. Innovations in understanding the biology of cervical cancer. Cancer S 98(9):2064-9, 2003.
7. Wolf JK, Franco EL, Arbeit JM, Shroyer KR, Wu TC, Runowicz CD, Tortolero-Luna G, Herrero R, Crum CP. Innovations in understanding the biology of cervical cancer. Cancer S 98(9)(9 Suppl):2064-9, 2003. PMID: 14603543.
8. Wolf JK, Jenkins AD. Gene therapy for ovarian cancer (review). Int J Oncol 21(3)(3):461-8, 9/2002. PMID: 12168087.
9. Wolf JK, Coleman RL. Commentary on, Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYZ-015(dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. Vasey, et al. J Clin Oncol 2002;20:1562-9". Women's Oncol Rev 2:325-7, 2002.
10. Wolf JK, Ramirez PT. The molecular biology of cervical cancer. Cancer Invest 19(6)(6):621-9, 2001. PMID: 11486705.
11. Wolf JK, Wharton JT. Wild-type p53 overexpression: what role in tumorigenesis? Gynecol Oncol 60(3):337-8, 3/1996. PMID: 8774635.
12. Wolf JK. Management of wound complications. Clin Consults in Ob/Gyn 8:79-84, 1996.

Editorials
1. Wolf JK, Wharton JT. Wild-type p53 overexpression: what role in tumorigenesis? Gynecol Oncol 60(3):337-8, 1996.
Other Articles
1. Herzog, Coleman R, McGuire, Monk B, Spriggs D, Wolf JK. Patterns of Practice in Selected Gynecologic Malignancies. Colloquium at the Annual Meeting on Women's Cancer 2005 36th Annual Meeting of the Society of Gynecologic Oncologist . (SGO Monograph), 2005.
2. Wolf JK. Gynecologic Cancer Treatment Update (Highlights from ASCO 2003). Vital Signs Monograph, Fall, 2003.

Abstracts
1. Schmeler KM, Vadhan-Raj S, Ramirez PT, Cohen L, Garcia ME, Bassett RL, Iyer RB, Mueller P, Levenback CL, Wolf JK, Gershenson DM, Freedman RS. A phase II study of chemoimmunotherapy for the treatment. Gynecologic Oncology 108(S1):S112 (#253), 3/2008.
2. Wong KK, Tung C, Yeung CS, Zu Z, Tsang YT, Deavers M, Wolf J, Lu K, Birrer M, Mok SC, Gershenson D. Decrease in the expression of BCMP11 during progression from low-malignant-potential to low-grade ovarian serous carcinoma. Gynecologic Oncology 108(S1):S51 (#113), 3/2008.
3. Smith JA, Gaikwad A, Naik B, Wolf JK, Zu Z, Cohen L. In vitro evaluation of HuaChanSu alone and in combination with antineoplastic agents in human ovarian and endometrial cancer cell lines. 3rd International Conference of the Society for Integrative Oncology, Boston, MA In Press, 11/2006.
4. Smith JA, Zu Z, Kunther A, Wolf JK, Gaikwad A, Cohen L. In vitro evaluation of HuaChanSu alone and in combination with antineoplastic agents in human ovarian and endometrial cancer cell lines. North American Research Conference on Complimentary and Integrative Medicine, Edmonton, AB, Canada A8:15, 5/2006.
5. Slomovitz B, Lu K, Burke TW, Soliman PT, Schmeler K, Munsell M, Johnston T, Coleman R, Ramondetta L, Gershenson DM, Wolf JK. mTOR is a rational target for the treatment of endometrial cancer: Preliminary results of a phase II study of RAD001 for patients with recurrent endometrial cancer. Gynecol Oncol 101(1):S110, 2006.
6. Smith JA, Yu J, Coleman R, Wolf JK. Optimizing the treatment of recurrent platinum-resistant ovarian cancer using a human xenograft mouse model. Pharmacotherapy 26(10):Abstract #401, 2006.
7. Smith JA, Gaikwad A, Ramondetta L, Wolf JK. Potentiation of cytotoxic agents in endometrial cancer cell lines when co-administered with gefitinib, an epidermal growth factor receptor (EGFR)-selective tyrosine inhibitors. Journal Oncology Pharmacy Practice 12(1):Abstract#6, 2006.
8. Coleman R, Broaddus RR, Bodurka DC, Wolf JK, Burke TW, Kavanagh JJ, Ramirez PT, Gershenson DM. A phase II study of Imatinib Mesylate in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer of fallopian tube cancer. Proceedings of Society of Gynecologic Oncologists 36th Annual Meeting 12:76, 3/2005.
9. Frumovitz M, Coleman RL, Gayed IW, Ramirez PT, Wolf JK, Levenback C. Utility of preoperative lymphoscintigraphy in patients undergoing radical hysterectomy and pelvic lymphadenectomy for cervical cancer. Proceedings of Society of Gynecologic Oncologists 36th Annual Meeting 180:135, 3/2005.
10. Crotzer DR, Wolf JK, Broaddus RR, Ramondetta LM. A retrospective analysis of clinical outcomes in patients treated for malignant mixed mesodermal tumors of the ovary and uterus with an evaluation of molecular marker expression. JCO 23(16S-I):481, 2005.
11. Slomovitz BM, Coleman RL, Soliman PT, Ramondetta LM, Wolf J, Sun CC, Gershenson DM, Burke TW, Lu KH. Is there a survival difference between clear cell and serous carcinoma of the endometrium? A stage and age-matched cohort study. JCO 23(16S-I):474, 2005.
12. Bodurka DC, Sun CC, Weaver CB, Bethancourt DL, Fitzgerald MA, Wolf JK, Gershenson DM, Kavanagh JJ, Munsell MF, Donato ML. Longitudinal assessment of quality of life (QOL) of patients (pts) with ovarian cancer (ovca) receiving high-dose or conventional-dose chemotherapy (CDCT). JCO 23(16S-I):470, 2005.
13. Sun CC, Bodurka DC, Weaver CB, Bethancourt DL, Fitzgerald MA, Wolf JK, Gershenson DM, Kavanagh JJ, Munsell MF, Donato ML. Preferences (PREFs) over time of chemo-experienced versus chemo-naïve patients (pts) for treatment-related side effects (SEs). JCO 23(16S-I):784, 2005.
14. Slomovitz BM, Wu W, Broaddus RR, Soliman PT, Wolf J, Sun CC, Bodurka DC, Gershenson DM, Lu KH. mTor inhibition is a rational target for the treatment for endometrial cancer. Proceedings of American Society of Clinical Oncology 40th Annual Meeting 23:466, 6/2004.
15. Sun CC, Donato ML, Wolf JK, Weaver CB, Fitzgerald MA, Gershenson DM, Bodurka DC. Preferences (PREF) over time of patients (pts) with ovarian cancer (OVCA) receiving conventional dose platinum-based chemotherapy (CDCT). Proceedings of American Society of Clinical Oncology 40th Annual Meeting 23:781, 6/2004.
16. Jenkins AD, Schimp V, Modesitt S, Ramirez PT, Zu Z, Wolf JK. Liposome-mediated p53 tumor suppression for ovarian cancer. Proceedings of American Association for Cancer Research 95th Annual Meeting 45:1061, 3/2004.
17. Bodurka DC, Apte SM, Wolf JK, Gershenson DM, Levenback C. Phase II trial of paclitaxel in advanced adenocarcinoma of the cervix. Proceedings of Society of Gynecologic Oncologists 35th Annual Meeting 80:111, 3/2004.
18. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C. A pilot study of cisplatin, Ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 22:474, 6/2003.
19. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C. A pilot study of cisplatin, Ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol 22(2):474, 6/2003. e-Pub 2/9/2007. PMID: 17292457.
20. Bodurka DC, Sun CC, Weaver CB, Jennings J, Melancon CH, Bevers MW, Wolf JK, Ramirez PT, Gershenson DM, Lairson DR. Ovarian cancer (OV CA): The cost of caregiving. Proceedings of American Society of Clinical Oncology 39th Annual Meeting 22:524, 6/2003.
21. Basen-Engquist K, De Moor C, Escalante CP, Wolf JK, Bodurka DC, Carmack Taylor C, Levenback CF, Kavanagh JJ, George G, Manzullo EF. Patterns of fatigue in ovarian cancer patients receiving chemotherapy. Proceedings of American Society of Clinical Oncology 39th Annual Meeting 22:743, 6/2003.
22. Sun CC, Bodurka DC, Weaver CB, Fitzgerald MA, Wolf JK, Levenback C, Kavanagh JJ, Palmer L, Gershenson DM, Rubenstein EB. Preferences (PREF) for side effects (SEs) of chemotherapy (CHEMO): How much is too much and how long is too long? Proceedings of American Society of Clinical Oncology 39th Annual Meeting 22:743, 6/2003.
23. Crotzer DR, Zu Z, Wolf JK. Suppression of growth of ovarian cancer cells following adenovirus-mediated transfection of lipid phosphate phosphatase (LPP). American Association for Cancer Research Annual Meeting, Toronto, Ontario, Canada, 4/2003.
24. Schimp VL, Worley C, Brunello S, Levenback CC, Wolf JK, Sun CC, Bodurka DC, Ramirez PT. Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol 98:121, 3/2003.
25. Schimp VL, Worley C, Brunello S, Levenback CC, Wolf JK, Sun CC, Bodurka DC, Ramirez PT. Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. Gynecol Oncol 98(2):121, 3/2003. PMID: 14766251.
26. Schimp VL, Modesitt SC, Jenkins AD, Zu Z, Ramirez PT, Gershenson DM, Wolf JK. In vivo adenovirus-mediated p16 tumor suppressor gene therapy in ovarian cancer. Proceedings of American Association for Cancer Research 93rd Annual Meeting 43:803, 3/2002.
27. Schimp VL, Ramondetta L, Jenkins AD, Modesitt SC, Zu Z, Burke TW, Wolf JK. In Vivo adenovirus-mediated p53, p21, and p16 tumor suppressor therapy in uterine papillary serous adenocarcinoma. Proceedings of American Association for Cancer Research 93rd Annual Meeting 43:83, 3/2002.
28. Anderson ML, Bodurka DC, White K, Sun CC, Wolf JK, Burke TW. Outcome of patients undergoing surgical resection of recurrent leiomyosarcoma. Proceedings of Society of Gynecologic Oncologists 33rd Annual Meeting 176:127, 3/2002.
29. Oh J, Ramondetta LM, Fritsche HA, Bast Jr RC, Mills GB, Wolf JK. Serum IGF-1, IGFBP-2, and IGFBP-3 in advanced ovarian cancer. Proceedings of American Association for Cancer Research 93rd Annual Meeting 43:189, 3/2002.
30. Alberts DS, Wolf J, Muntz H, Hatch K, Carrier A, Egger S, Heald A. A phase I, dose-escalation trial of E1A gene transfer with chemotherapy for treatment of advanced ovarian cancer. Proceedings of American Society of Clinical Oncology 16:18A, 2002.
31. Alberts DS, Wolf J, Muntz H, Hatch K, Carrier A, Eggert S, Heald A. A Phase I, dose-escalation trial of E1A gene transfer with chemotherapy for treatment of advanced ovarian cancer. Proceedings of the American Society of Clinical Oncology 38th Annual Meeting 21(1):18a, 2002.
32. Wolf JK, Sun CC, Verschraegen CF, Jenkins AD, Branham DW, Bodurka DC. A phase II study of Xeloda inpatients with chemotherapy resistant recurrent ovarian cancers. Proceedings of the American Society of Clinical Oncology 38th Annual Meeting 21(1):224a, 2002.
33. Ramondetta LM, Broaddus R, Wolf JK, Levenback C, Bevers M, Burke TW. A phase II trial of cisplatin and ifosfamide/mesna in patients with advanced or recurrent uterine mixed Mullerian tumors. Proceedings of the American Society of Clinical Oncology 38th Annual Meeting 21(1):213a, 2002.

Book Chapters
1. Smith JA, Wolf JK. Ovarian Cancer. In: Pharmacotherapy: A Pathophysiologic Approach, 7th Edition. Ed(s) Dipro JT, Talbert RL, Yee GC, Matze GR, Wells BG, Posey LM. McGraw Hill. In Press.
2. Slomovitz BM, Soliman PT, Wolf JK. Gynecologic Cancers. In: The M. D. Anderson Surgical Oncology Handbook, Fourth Edition. Ed(s) Barry W. Feig, David H. Berger, and George M. Fuhrman. Lippencott Williams & Wilkins: Philadelphia, PA, 520-563, 2006.
3. Tanyi JL, Crotzer D, Wolf JK, Yu S, Hasegawa Y, Lahad J, Wa Cheng K, Umezu-Goto M, Prestwich GD, Morris A, Newman RA, Felix EA, Lapis R, Mills GB. Lysophosphatidic Acid as a Targets for the Molecular Diagnosis and Therapy of Ovarian Cancer. A Review Article. In: Functional Lipidomics. Ed(s) Feng L, Prestwich GD. CRC Press Taylor & Francis Group: Boca Raton, FL, 101-123, 2005.
4. Wolf JK, Wharton JT. Surgery for Ovarian Cancer. In: Gynecologic Cancer. Ed(s) Gershenson DM, Eifel PJ, Kavanagh JJ, and Silva E. Springer-Verlag: New York, NY, 174-186, 2005.
5. Bevers MW, Bodurka Bevers DC, Wolf JK. Gynecologic Cancers. In: The M. D. Anderson Surgical Oncology Handbook, Third Edition. Ed(s) Barry W. Feig, David H. Berger, and George M. Fuhrman. Lippencott Williams & Wilkins: Philadelphia, PA, 445-490, 2003.
6. Wolf JK. Molecular Biology. In: ACS Atlas of Clinical Oncology: Cancer of the Female Lower Genital Tract. Ed(s) Eifel PJ, Levenback C. B.C. Decker, Inc: Hamilton London, 2001.
7. Wolf JK, Burke TW. Vulva/Vaginal Cancer. In: Practical Strategies in Obstetrics and Gynecology. Ed(s) Mitchell P. Dombrowski, S. Gene McNeeley, Kamran S. Moghissi, and Adnan R. Munkarah. W. B. Saunders Company: Philadelphia, 449-457, 2000.
8. Bevers MW, Bodurka Bevers DC, Wolf JK. Gynecologic Cancers. In: The M. D. Anderson Surgical Oncology Handbook, Second Edition. Ed(s) Barry W. Feig, David H Berger, and George M. Furhman. Lippincott Williams & Wilkins: Philadelphia, 377-424, 1998.
9. Wolf JK, Mills GB, Bast RC, et al. P53-mediated Gene Therapy. In: Ovarian Cancer. Ed(s) Frank Shart, Tony Blackett, Jonathan Berek and Robert Bast. Isis Medical Media Ltd: Oxford England, 259-27, 1998.
10. Hallum AV, III, Coleman RL, Wolf JK. Gynecologic Oncology. In: The M. D. Anderson Surgical Oncology Handbook. Ed(s) David H. Berger, Barry W. Feig, and George M. Fuhrman. Little Brown and Company: Boston, MA, 326-368, 1995.

Books (edited and written)
1. Wolf JK. Ovarian Cancer: Ask the Experts. Humana Press, Springer Science & Business Media: Totowa, NJ. In Press.

Last updated: 9/15/2009